Abzena and Angiex Partners as AGX101 Enters Phase 1 Clinical Trials
Angiex, a biopharmaceutical company focused on developing innovative therapies for solid cancers, has begun patient dosing for its Phase 1 clinical trial of AGX101, a…
Angiex, a biopharmaceutical company focused on developing innovative therapies for solid cancers, has begun patient dosing for its Phase 1 clinical trial of AGX101, a…
Abzena, an end-to-end integrated contract development and manufacturing organization (CDMO) for complex biologics and bioconjugates, has teamed up with Argonaut Manufacturing Services, Inc., a cGMP…
Abzena an end-to-end integrated CDMO for complex biologics and bioconjugates has launched EpiScreen 2.0, an enhanced bioassay platform for predicting and evaluating immunogenicity risks in…
Abzena, a CDMO specialising in complex biologics and bioconjugates, has unveiled a significant expansion at its Bristol, PA bioconjugate development and cGMP manufacturing site. The…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.